1Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer.report of a Canadian multicenter randomized trial. J Clin Oncol, 1988, 6:633-641.
2Woods RL, Williams CJ, Levi J, et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer,1990, 61:608-611.
3Quoix E, Dietemann A, Charbonneau J, et al. Is chemotherapy with cisplatin useful in non. small cell bronchial cancer at staging IV? Results of a randomized study. Bull Cancer, 1991, 78:341-346.
4Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer, 1989, 63:1271-1278
5Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Nat Cancer Inst, 1993,85:794-800.
6Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol, 1991, 9:1453-1461.
7Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol, 1999, 17:3188-3194.
8Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. Eur J Cancer, 1998, 34:1036-1044.
9Stephens RJ, Fairlamb D, Gower N, et al. The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc ASCO, 2002.USA:2002
10Zatloukal PV,Novakova L, Petruzelka L, et al. Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCBP) in patient with stage ⅢB and Ⅳ non-small cell lung cancer (NSCLC): Final results of Czech Lung Cancer Cooperative Group Phase Ⅲ R
